-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WtgQQqAK40h1N4YPCPwco+NF2WyxHNpDtRErD6DHgJ2lflcbo9e0HOfHfAOV/GdY
 uaHe7j/UFGXdWYahfWEAow==

<SEC-DOCUMENT>0000950123-10-002338.txt : 20100113
<SEC-HEADER>0000950123-10-002338.hdr.sgml : 20100113
<ACCEPTANCE-DATETIME>20100113171334
ACCESSION NUMBER:		0000950123-10-002338
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20100113
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100113
DATE AS OF CHANGE:		20100113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		10525786

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c94649e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">
<DIV style="font-size: 10pt">
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>

<P style="font-size: 14pt" align="center"><B>UNITED STATES<BR>
SECURITIES AND
EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P style="font-size: 18pt" align="center"><B>FORM 8-K</B>

<P style="font-size: 12pt" align="center"><B>CURRENT REPORT<BR>
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P style="font-size: 10pt" align="center"><B>Date of Report (Date of earliest
event reported): January 13, 2010</B>


<P style="font-size: 24pt" align="center"><B>CYCLACEL PHARMACEUTICALS,
INC.<BR>
</B><FONT style="font-size: 10pt">(Exact name of registrant as
specified in its charter) </FONT>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="32%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="33%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="32%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>Delaware</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>0-50626</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>91-1707622</B></TD>
 </TR>
 <TR valign="top">
  <TD>(State or other Jurisdiction of Incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD>(Commission File Number)</TD>
  <TD>&nbsp;</TD>
  <TD>(IRS Employer Identification No.)</TD>
 </TR>

</TABLE>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="100%" border="0">

 <TR>
  <TD width="49%">&nbsp;</TD>
  <TD width="1%">&nbsp;</TD>
  <TD width="49%">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD style="border-bottom: #000000 1px solid"><B>200 Connell Drive, Suite
1500<BR>
Berkeley Heights, New Jersey <BR>
</B></TD>
  <TD>&nbsp;</TD>
  <TD style="border-bottom: #000000 1px solid"><B>07922</B></TD>
 </TR>
 <TR valign="top">
  <TD>(Address of Principal Executive Offices)</TD>
  <TD>&nbsp;</TD>
  <TD>(Zip Code)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="center">Registrant&#8217;s telephone number,
including area code: <B>(908) 517-7330</B>
<TABLE style="font-size: 10pt; text-align: center" cellspacing="0"
cellpadding="0" width="30%" border="0">

 <TR>
  <TD width="100%">&nbsp;</TD>
 </TR>
 <TR>
  <TD style="border-bottom: #000000 1px solid" nowrap><B>&nbsp;</B></TD>
 </TR>
 <TR>
  <TD nowrap>(Former name or former address if changed since last report.)</TD>
 </TR>

</TABLE>


<P style="font-size: 10pt" align="left">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:

<P style="font-size: 10pt" align="left"><FONT face="Wingdings">o</FONT> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)<BR>
<BR>
<FONT face="Wingdings">o</FONT> Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
<BR>
<FONT
face="Wingdings">o</FONT> Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<DIV style="margin-top: 10pt; font-size: 1pt; width: 100%; border-bottom: black 1pt solid">&nbsp;</DIV>
<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid">&nbsp;</DIV>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>ITEM 8.01 Other Events.</B>

<P style="font-size: 10pt; text-indent: 4%" align="left">On January&nbsp;13,
2010, Cyclacel Pharmaceuticals, Inc. (the &#8220;<B>Company</B>&#8221;)
completed the sale of 2,850,000 units in its previously disclosed
&#8220;registered direct&#8221; offering (the &#8220;<B>Offering</B>&#8221;) to
certain institutional investors. Each unit (&#8220;<B>Unit</B>&#8221;) was sold
at a purchase price of $2.51 per Unit and consists of one share of the
Company&#8217;s common stock, par value $0.001 per share (the &#8220;<B>Common
Stock</B>&#8221;), and one warrant to purchase 0.25 of one share of Common
Stock (each, a &#8220;<B>Warrant</B>,&#8221; and collectively, the
&#8220;<B>Warrants</B>&#8221;). The Warrants have a five-year term from the
date of issuance, are exercisable beginning six months from the date of
issuance and will be exercisable at an exercise price of $3.26 per share of
Common Stock.

<P style="font-size: 10pt; text-indent: 4%" align="left">ROTH Capital Partners,
LLC acted as the placement agent for the Offering (the &#8220;<B>Placement
Agent</B>&#8221;). Merriman Curhan Ford served as financial advisor.&nbsp;

<P style="font-size: 10pt; text-indent: 4%" align="left">The net proceeds to
the Company from the sale of the Units, after deducting for the Placement
Agent&#8217;s fees and offering expenses, is approximately $6.6&nbsp;million.
Following the issuance of the 2,850,000 shares, the Company has
28,964,653
shares of Common Stock issued and outstanding.

<P style="font-size: 10pt; text-indent: 4%" align="left">On January&nbsp;13,
2010, the Company issued a press release announcing the closing of the Offering
described above under item 1.01 of this Current Report on Form 8-K. A copy of
the press release is attached hereto as Exhibits 99.1 and incorporated herein
by this reference.

<P style="font-size: 10pt; text-indent: 4%" align="left">Neither the filing of
the press release as an exhibit to this Current Report on Form 8-K nor the
inclusion in the press release of a reference to our internet address shall,
under any circumstances, be deemed to incorporate the information available at
our internet address into this Current Report on Form 8-K. The information
available at our internet address is not part of this Current Report on Form
8-K or any other report filed by us with the SEC.

<P style="font-size: 10pt" align="left"><B>ITEM 9.01 &nbsp; Financial
Statements and Exhibits.</B>

<P style="font-size: 10pt" align="left">(d)&nbsp; &nbsp;Exhibits:
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">No. </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Description</TD>
 </TR>
 <TR style="font-size: 1px">
  <TD style="border-top: #000000 1px solid" valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD style="border-top: #000000 1px solid" valign="top"
align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release dated January&nbsp;13, 2010</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="center"><B>SIGNATURES</B>

<P style="font-size: 10pt; text-indent: 4%" align="left">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.

<P style="font-size: 10pt; text-indent: 48%" align="left"><B>CYCLACEL
PHARMACEUTICALS, INC.</B>

<P style="font-size: 10pt" align="left">Dated: January&nbsp;13, 2010

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%" border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="48%">&nbsp;</TD>
  <TD width="4%">&nbsp;</TD>
  <TD width="48%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD valign="top">By:</TD>
  <TD valign="top" align="left" style="border-bottom: #000000 1px solid">/s/ Paul McBarron</TD>
 </TR>
 <TR valign="bottom">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Name: Paul McBarron<BR>
Title: Executive Vice President &#8212; Finance, Chief<BR>
Financial Officer and Chief Operating Officer</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>


<P style="font-size: 10pt" align="left">&nbsp;

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV
style="margin-left: 0.25in; width: 7.2in; font-family: 'Times New Roman',Times,serif">

<P style="font-size: 10pt" align="left"><B>Exhibit&nbsp;Index:</B>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" cellpadding="0" width="100%"
border="0">
<!-- Begin Table Head -->

 <TR valign="bottom">
  <TD width="8%">&nbsp;</TD>
  <TD width="5%">&nbsp;</TD>
  <TD width="87%">&nbsp;</TD>
 </TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">No. </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Description</TD>
 </TR>
 <TR style="font-size: 1px">
  <TD style="border-top: #000000 1px solid" valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">&nbsp;</DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD style="border-top: #000000 1px solid" valign="top"
align="left">&nbsp;</TD>
 </TR>
 <TR valign="bottom">
  <TD valign="top">
<DIV style="margin-left: 0px; text-indent: 0px">99.1 </DIV>
</TD>
  <TD>&nbsp;</TD>
  <TD valign="top" align="left">Press Release dated January&nbsp;13, 2010</TD>
 </TR>
<!-- End Table Body -->

</TABLE>
</DIV>

<P style="font-size: 10pt" align="center">&nbsp;

<P style="display: none; font-size: 10pt" align="center">4
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c94649exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">

<P align="right" style="font-size: 10pt"><B>Exhibit 99.1</B>

<DIV align="left" style="font-size: 10pt"><IMG src="c94649p9464901.gif" alt="(LOGO)">
</DIV>
<P align="right" style="margin-left:46%; font-size: 10pt; margin-top: -44pt">Cyclacel Pharmaceuticals, Inc.

 <P>&nbsp;
<P align="center" style="font-size: 10pt"><B>P&nbsp;R&nbsp;E&nbsp;S&nbsp;S&nbsp;&nbsp;&nbsp;R&nbsp;E&nbsp;L&nbsp;E&nbsp;A&nbsp;S&nbsp;E</B>

<P align="center" style="font-size: 10pt"><B>CYCLACEL COMPLETES PREVIOUSLY ANNOUNCED REGISTERED DIRECT OFFERING</B>



<P align="left" style="font-size: 10pt"><B>Berkeley Heights, NJ, January&nbsp;13, 2010 </B>&#150; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; &#147;Cyclacel&#148; or the
&#147;Company&#148;) announced today that it completed its previously announced registered direct offering through the sale of
shares of its common stock and warrants for gross proceeds of $7.2&nbsp;million, before deducting placement agent fees and
offering expenses, in a registered direct offering with select institutional investors. The offer included the sale
and issuance of 2.85&nbsp;million units, each unit consisting of one share of the Company&#146;s common stock and a warrant to
purchase 0.25 shares of common stock, at a purchase price of $2.51 per unit. The warrants, which represent the right
to acquire an aggregate of 712,500 shares of common stock at an exercise price of $3.26 per share, have a five-year
term from the date of issuance and are exercisable beginning six months after the date of issuance.


<P align="left" style="font-size: 10pt">The units were offered and sold pursuant to a prospectus supplement dated January&nbsp;11, 2010 and an accompanying
prospectus dated February&nbsp;12, 2007, pursuant to the Company&#146;s effective shelf registration statement previously filed
with the Securities and Exchange Commission.


<P align="left" style="font-size: 10pt">Roth Capital Partners, LLC served as the sole placement agent for the offering. Merriman Curhan Ford served as
financial advisor.


<P align="left" style="font-size: 10pt">This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any
sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such jurisdiction. Any offer will be made only by means
of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of
the final prospectus supplement together with the accompanying prospectus can be obtained at the SEC&#146;s website at
<U>http://www.sec.gov</U> or from Roth Capital Partners, LLC at 24 Corporate Plaza, Newport Beach, CA 92660.


<P align="left" style="font-size: 10pt"><B>About Cyclacel Pharmaceuticals, Inc.</B>


<P align="left" style="font-size: 10pt">Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel,
mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are
in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for
the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. The Company plans
to submit a Special Protocol Assessment (SPA)&nbsp;request for a pivotal study with sapacitabine during the first quarter of
2010. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the
treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an
Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel&#146;s ALIGN
Pharmaceuticals subsidiary markets directly in the U.S. Xclair&#174; Cream for radiation dermatitis, Numoisyn&#174; Liquid and
Numoisyn&#174; Lozenges for xerostomia. Cyclacel&#146;s strategy is to build a diversified biopharmaceutical business focused in
hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug
candidates. Please visit <U>www.cyclacel.com</U> for additional information.


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="87%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-family: Wingdings">&#254;</FONT> 200 Connell Drive, Suite&nbsp;1500, Berkeley Heights, NJ&nbsp; 07922 USA T: &#043;1 (908)&nbsp;517 7330 F: &#043;1 (866)&nbsp;271 3466</TD>
</TR>
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><FONT style="font-family: Wingdings">&#168;</FONT> Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel &#043;44 1382 206 062 Fax &#043;44 1382 206 067</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt"><U>www.cyclacel.com</U> &#150; <U>info@cyclacel.com</U>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: Arial,sans-serif; margin-left: .25in; width: 7.20in">




<P align="left" style="font-size: 10pt"><B>Risk factors</B>


<P align="left" style="font-size: 10pt">This news release contains certain forward-looking statements that involve risks and uncertainties that could cause
actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding,
among other things, the efficacy, safety, and intended utilization of Cyclacel&#146;s product candidates, the conduct and
results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans
regarding partnering activities. Factors that may cause actual results to differ materially include the risk that
product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or
efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its
products, the risks associated with reliance on outside financing to meet capital requirements, and the risks
associated with reliance on collaborative partners for further clinical trials, development and commercialization of
product candidates. You are urged to consider statements that include the words &#147;may,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148;
&#147;should,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;intends,&#148; &#147;continues,&#148;
&#147;forecast,&#148; &#147;designed,&#148; &#147;goal,&#148; or the negative of those words or other comparable words to be uncertain and
forward-looking. These factors and others are more fully discussed under &#147;Risk Factors&#148; in the Annual Report on Form
10-K for the year ended December&nbsp;31, 2008, as supplemented by&nbsp;the interim quarterly reports, filed with the SEC.


<P align="left" style="font-size: 10pt"><B>Contacts for Cyclacel Pharmaceuticals, Inc.</B>


<P align="left" style="font-size: 10pt">Investors/Media:
<BR>
Corey Sohmer, (908)&nbsp;517-7330
<BR>
<U>csohmer@cyclacel.com</U>


<P align="left" style="font-size: 10pt">&#169; Copyright 2010 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&#174; are trademarks
of Cyclacel Pharmaceuticals, Inc. Numoisyn&#174; and Xclair&#174; are trademarks of Sinclair Pharma plc.


<P align="left" style="font-size: 10pt">SOURCE: Cyclacel Pharmaceuticals, Inc.


<P align="center" style="font-size: 10pt">2

<P align="center" style="font-size: 10pt; display: none">2




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c94649p9464901.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c94649p9464901.gif
M1TE&.#EAK@!"`'```"'Y!`$``/\`+`````"N`$(`A____X2$A`"4U@````"$
MUC&EWK6]O:WFO5*UWB&,YEK.YE)*4GNMYN_W]UIK6F/O:V/%:Q`90A!*6A#.
MYA"<G,7F[X3%[UKOYN9KK;5K[[5K:[40[[40:[5K*;40K;40*7N,YN9KC+5K
MSK5K2K40SK402K5K"+40C+40"*7F[ZV<K2D($#KO8SIKWH3>.CK>,3I:K82<
M.CJ<,3H9K3JM8SHIWH2MI83OI81K&3%K&80I&83>$!#>,1!:K82<$!"<,1`9
MK5JMI1#O8Q!KWA"M8Q`IWEKOI5IK&5HI&1!K&6-:[V,9[Q#OI6-KE&,IE(1:
MSH09SC'.I3K.8SI*WCJ,8SH(WH3.I81*&80(&5J,I1#.8Q!*WA",8Q`(WEK.
MI5I*&5H(&6-*E&,(E,[%Q=[O]RDA&7MK6JV<C(1KE`@9$*UKK>9K[^9K:^80
M[^80:^9K*>80K>80*:UKC.9KSN9K2N80SN802N9K".80C.80"&.46C%"&83O
MYH3O:S%K6C$98X0I6N:<K;6<[[6<:[5"[[5":[6<*;5"K;5"*83%:UHI6A`9
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M$!!KC&.M$!"M$!`IC!!**6-KSF,ISA#.M>:][V/..CK.$#I*C&.,.CJ,$#H(
MC&/.$!#.$!!*C&.,$!",$!`(C!!*"&-*SF,(SA#.E/?OO>;O8^;O*:WOG.;%
M8^;%*:W%G`B<YH2,M83.UO_6[PB$[XR<A`@`&?__Y@````C_`/\!&$BPH,&#
M*2P4N$>`@`"'`NX)F.BPX3T$%L@<W,BQH\>/($.*'$FRH\"29!0VG"C`441'
M"5K&;!FQH@`$%1J4W,FSI\^?'D^*;&"!(4L!"1PQ-&I4*5*7+A\2*)`"J-6K
M6+,"$`JRJ$.H1E=6'`LQ8LQ[+AOBU,JVK=N#7#M60/#090*&#1T50)!O58H*
M%?PB0%!`*@%'!.Y2%&#AK>/'5N-N3)'@*\6I"@`?U%FP0HH"B%DJK5A`(^33
MJ$%*-F@AKT2U*3@/;!`X'P(&"C!6,`T@90&+!"2&KI"ZN'&"JPDB@(AW+<$*
M%NA>EOI0P%[B`U,0.[QT*?;CX!\G_P>PG"8!8E4)KJ+;D/E$IU$M9@1`M&YP
MQ(W#ZW>;?#E:APK(1EEU[[5GF$,,Q<>83A7\!M-#^>PGH5:KM5:3`*L01$9Y
M+$&$@`*XX398:,&9=T]ZRZWTW80L^B19"MP=]MTJ33DT&!FR&42;`K\AB!@!
M"F0W&'$&+$"*/2TF25)<#51FUXR(_8A`>O1Y%MU@%OQ%4`KL'::6008,(.8`
M*BAIYD=Q<7C/=Q8^Y!P`7%:VTH\-)>#<9SX"6=`"8PZPQYF`;L05C!2Q698%
MG*W28X?4=3A5A@!8V-`C!3G0)RN!9HH<04VV1$!^<$*4`'8-CJ777JOP05A,
M$-E(7`H)KO\8YIAE:IJI4"E0A("&%)667753\;%B9_G\1I$C&3:0@D9C.!#`
M0$4N4*NM@9[4I$/$\&:LKP`PL-*;`$!GP;C+;KE==9`",$H:8BY`[;M;_3H1
MJ*T=9EH^+*W"V5ROM>=0`ADU4)^;!*G09X[P`GK2N05H&%5Z]19`:H_8@O9:
M:(C">0\QWZW;;L*V"D3&:U36FU\%#T5B6KT$3(GC;&04*]6:]#$;@`'J+F"&
M/R"?Z0]G`D7,,WT2):!3`[\5P%EY^?`&F&8#-2@5=F2P.\`8/0=J@`$-J-"`
M0.6!"B,!Z:WB$';+C1HU`JQ:Y!R^9`\TRI@X9VWF*"J<,88-9_S_TT!4IB$]
MU=$,09K/5!IMZ-!>"14@)P(::28P``&4$0#"=D]HP!C&*#)&`/^@W#*G$`ZT
MBEX,GA?Y0QD7Y`^>!&`W2ADK8)YYBV,8<(8-NO]C]J?JV3O0;RC&'B[B'EF`
MK-QBCG)[H"H8X(\*H_QCP43?*3!Z;TA%#3P`]S0LTBC.Y^Y3`Y\'$,`9HS0P
MROJV-W!&`%@7U(`!Z@=`?<$!.`^2[I<#"=[RQS4`_$P%Q3C#&1(XO[HU(('^
MVPCY=/*/Y3A"-LO)#XPB1!X!Z`0!Q+`=1T@Q@)^,P@']Z).8+L<N=QVD&`/H
M1P3'P"<5#@!G_BC#`,X`D@98+0!#V\@9_TAH0YW,RH8N--@-0_(/ANQJ-K_!
MSN&P<X_&-(!F(['!LWIB@!4,(`T+H!_^P@@`)=:-(![C(7W.(*8R.*`88[!'
M`$A1-Q).JR,&8U<_1&BI`9#"&"H8@PH<4(;RB<D,Q4AD,6X&+3&=,2@/"=)`
MR!"<I=TC=<11B$@"L(`@\F16"^!%1_A$"H-8RH5E%),#-L*S!I#0!B#A4S%(
M^$B"\"D-:MS(&)K'D5G5#TT/8<!SIC(;.V7'$0/!B$A48(R?-(!/91`A\P;`
M#X+L<@#^\^$`4,F1/>SP(W-+`P#XL<V#*/&.!O&',\3T2X-<LY8<^<=$.!@N
M`1"#(#<QG?@@!_\2^EG%E_T<0#0'0L(M4DZ@TB3H`&#I$3,,P`P`N&8$Z4-"
M;NJ2G;UT)!-9IR%B#N0BIML5TA(*+9*&Q%)E$$E!`<#&E-JRG!\A82XYDL+Z
M\<F@/].H1R2:T26JQB&@0MD3`;"]]?1&:2'Q9$]8,8`FB&16!JAI0<1TAH0V
MP)L,Y8C!2CF0EA9$B1.]Z`"<E;_^-?)J3"P,J,`G/O)(DDO)-"E6;CJ2/H[5
M(.Q"YT;LZ!$^57.2[#JC#7CID;G9T*?O9.)RZ`D`QRGGB16XQT`L,"S'K'0H
M[!IH0?(*$AUF]2"[3$..++7*KA*V([,B:_[\!U4F'DZ2R42FZ1(P203_Z"0%
MZ8(,G_XT$CZ5MB`Z_&U'9-J1`/B1?&,@'QME.)!KME.L825(:U5CMJ%&2@"D
MNH=I$)"AE,C5*L;=HU)'>5>#D/(CKEPH1[1Y6*K.AET&Y8AS>_K<>%9@>]Y+
M5P$@Y0Q)^@4UAK5H7\M;D&O^M2/>G&E!PI0&!SA@`1!>@`-(R%4`.!2M'3%L
M?9NK4S2!CP"RN>)0BZ4<XA"%-X\Q[@#B.V#AOI1,'N'K1N@*6HSVAEVDB*YT
M3PLF&WMX.2MB@&2+B1VX]J9UD.DC*0*)7+T=Q+<;2>\V-T<^`_"C?@4=17+'
MD%Q_&%;'`&#J;PWPP\VA#W\ZN2:3M\Q:JFI9_\O)%10`S`;;>E(I-P11`*2@
M4]F"D"&W/@F`U53(8@!`.<IV56&9&J!#)!Y4P`0AIS@)PHL:BFG0ACRL"X^H
M0DB+S*/*:2L`U);,]"AK%96U$HJ=:0\SL*(,90AC="<,T0R?H0E[*`,IPL@9
M/Y`"UF5(`ZQ7N8`RZ!6-OT8G_B:\`E8X0`4\JX"N@PUK89=V#+\&MK#=*&?R
M&&^8WZ&,;!A`)3($!M6X1?5W&K#JYX7,>]8ECZBCPRD%(%E@^,[17/KL[FI!
M\8*=(4!N!U.05>A9FN)J=[]OM:7O;0F[!2$XIQ*2)3+@"##CHJS]%+[P)''E
M-ZMFFT$4\(AA`<8OY/_:C4'F`NB.*XDK]XTWTI"ZI0(@N8?1:;G+/6Z0Y5`)
MBK:U7VY6P?'G*"3H._>W07Z#L";17$-7HNQN:(-Q++4;:DF?D&1BWG2V]3DP
MT0$1EE`=Y=;P.^O&60V,XCW93UGU(PWB%MHEE)S6"/,@<TF`OG;2H'OH?.[@
M&0^^V)X=QVD<)"E!P#T8T(#Q`C[PR<,OW@F#$<KFFS;C6@A?1/CGQZ?](S"2
M^V8JD)O![*4`>QE,;#Q2`6(\W?.0&<]S$//SCK`;1T6W7VOX"7O4R#[B+3L[
M3RCC\-Z?YO>=J0SO?X*GY1O_^"1YG?*%+Y=\3/_YGR^)LGYS$95[Q-PJZ3Y,
M]H^#_.H_@B&IS_BX<E.8X'#WN^.GT%7`SJ,$H-[UY()__-ORC_[[__\`&(`"
A.(`$6(`&>(`(F(`*N(`,V(`.^(`0&($2.($4*($!`0`[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
